Unlock instant, AI-driven research and patent intelligence for your innovation.

Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases

a technology of scavenger receptor and inhibitor, which is applied in the direction of amide active ingredients, drug compositions, tetracycline active ingredients, etc., can solve the problem of even more depressing reality, and achieve the effect of inhibiting high density lipoprotein (hdl) uptak

Inactive Publication Date: 2009-12-31
INST DE MEDICINA MOLECULAR FACULDADE DE MEDICINA UNIVE DE LISBOA +1
View PDF6 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0256]The scavenger receptor class inhibitor usable according to the present invention may be coated with or admixed with a material that delays disintegration and / or absorption of the active agent in the gastrointestinal tract (e.g., glyceryl monostearate or glyceryl distearate may be used). Thus, the sustained release of an active agent may be achieved over many hours and, if necessary, the active agent can be protected from being degraded within the stomach. Pharmaceutical compositions for oral administration may be formulated to facilitate release of an active agent at a particular gastrointestinal location due to specific pH or enzymatic conditions.

Problems solved by technology

Malaria is a major health problem, mainly in Sub-Saharan Africa and in some parts of Asia and South America.
This reality is even more depressing realising that a death from malaria occurs every 30 seconds.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases
  • Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases
  • Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases

Examples

Experimental program
Comparison scheme
Effect test

example 1

Cell Cultivation and Seeding

[0288]Huh human hepatoma cells, were cultivated in RPMI (Gibco / Invitrogen) medium containing 10% FBS, 1% non-essential amino acid solution (Gibco / Invitrogen), 1% penicillin / streptomycin solution (Gibco / Invitrogen), 1% glutamine (Gibco / Invitrogen) and 1% Hepes pH 8 (Gibco / Invitrogen).

[0289]Hepa 1-6 cells were cultured in complete DMEM medium (Gibco / Invitrogen) supplemented with 10% fetal calf serum (Gibco / Invitrogen) and 1% penicillin / streptomycin (Gibco / Invitrogen) incubated at 37° C. and 5% CO2.

[0290]Cells were split twice per week by seeding 106 cells in 15 ml complete medium in 75 ml culture flasks (Nunc). For passaging, cells were detached from the flask by incubation with 3 ml Trypsin solution (Gibco / Invitrogen) for 5 min at 37° C. Trypsin was inactivated by adding 10 ml of complete medium to the flask.

[0291]Cell based experiments were performed in black, optical 96 well plates (Costar / Coming). 4000-6000 cells per well were seeded in a volume of 100 ...

example 2

Isolation of Sporozoites of Plasmodium berghei ANKA or Plasmodium yoelii from Mosquitoes

[0293]Sporozoites were obtained from Anopheles stephensi mosquitoes infected with P. berghei ANKA or P. yoelii. Salivary glands were dissected and collected in RPMI medium (GIBCO) on ice. Collected tissues were gently ground in the medium to release sporozoites. Tissue fragments were removed by centrifugation at 40×g for 3 min, and sporozoites were collected from the supernatant.

example 3

Treatment of Cells with Chemical Compounds Prior to Infection

[0294]Blt-1, Blt-2, and Blt-4 were purchased from ChemBridge Corporation (San Diego, USA). Ezetimibe (for chemical structure see FIG. 6 and structure (XXVI)) was derived from powdered Ezeterol tablets (Essex Pharma, UK). Each compound was dissolved in DMSO at a final concentration of 50 mM. 48 hours after seeding of 6000 Huh-7 cells per well, growth medium was replaced by fresh complete culture medium, containing the compounds in 4 different concentrations, generated by dilution series of the compound stock solutions in complete growth medium: 8 μM; 1.6 μM; 320 nM; 64 nM. Controls media were prepared according to DMSO concentrations in the 4 compound dilutions, i.e. 0.016%; 0.0032%; 0.00064%; 0.000128%. Huh-7 cells were equilibrated for 1 h with compound / DMSO-containing medium at 37° C. before infection with 10,000 sporozoites per well (FIG. 1 to 4).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Massaaaaaaaaaa
Angleaaaaaaaaaa
Login to View More

Abstract

The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and / or prophylaxis against infections, involving liver cells and / or hematopoietic cells, in particular malaria.

Description

[0001]The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for therapy of and / or prophylaxis against infections, involving liver cells and / or hematopoietic cells, in particular malaria.[0002]Malaria is a major health problem, mainly in Sub-Saharan Africa and in some parts of Asia and South America. Each year there are about 600 million new clinical cases and at least one million individuals, mostly children, die from malaria. This reality is even more depressing realising that a death from malaria occurs every 30 seconds. Over 90% of the deaths occur in Africa. Within the last 10 to 15 years the burden of malaria has been increasing mainly because of the emergence of Plasmodium falciparum and P. vivax variants that are resistant to cheap drugs such as chloroquine, mefloquine, and pyrimethamine. In the light of the failure of the development of a malaria vaccine, despite intensive efforts,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395G01N33/53C12Q1/02A61K31/7088A61K31/397A61K31/55A61K31/5365A61K31/505A61K31/4439A61K31/428A61K31/416A61K31/403A61K31/352A61K31/175A61K31/17A61K31/16A61K31/155
CPCA61K31/122A61K31/137A61K31/15A61K31/155A61K31/165A61K31/17A61K31/35A61K31/397A61K31/4706A61K31/49A61K31/505A61K31/536A61K31/65G01N33/5047G01N33/5067G01N33/56905G01N2333/445G01N2500/00A61P33/02A61P33/04A61P33/06Y02A50/30A61K2300/00
Inventor HANNUS, MICHAELMARTIN, CECILIEMOTA, MARIA M.PRUDENCIO, MIGUELRODRIGUES, CHRISTINA DIAS
Owner INST DE MEDICINA MOLECULAR FACULDADE DE MEDICINA UNIVE DE LISBOA